Official Title
Incidence of Severe COVID-19 Infection in Patients With Chronic Lymphocytic Leukemia or Indolent B-cell Non-Hodgkin Lymphoma Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy: an Observational Study by the GIMEMA Working Party on Chronic Lymphoproliferative Disorders and by the Fondazione Italiana Linfomi
Brief Summary

This is an observational retrospective and prospective multicenter study aimed atdescribing the role of the COVID -19 prophylaxis with Tixagevimab and Cilgavimab in CLLor indolent B-NHL patients who received first COVID-19 prophylaxis dose between March2022 and October 2022.

Detailed Description

This is an observational retrospective and prospective multicenter study aimed at
describing the role of the COVID -19 prophylaxis with Tixagevimab and Cilgavimab in CLL
or indolent B-NHL patients.

All CLL or indolent B-cell NHL patients (follicular lymphoma, marginal zone lymphoma,
lymphoplasmacytic lymphoma) who received first COVID-19 prophylaxis dose with Tixagevimab
and Cilgavimab according to AIFA indication between March 2022 and October 2022 will be
included in the study.

Each patient will be followed for a maximum of 12 months from the first COVID-19
prophylaxis dose.

Recruiting
Chronic Lymphocytic Leukemia
Indolent B-Cell Non-Hodgkin Lymphoma
COVID-19
Eligibility Criteria

Inclusion Criteria:

1. Age ≥ 18 years

2. Patient with CLL or indolent B-NHL who received the first COVID-19 prophylaxis dose
with Tixagevimab and Cilgavimab as per label indication between March 2022 and
October 2022.

3. Signed informed consent, if applicable

Exclusion Criteria:

None

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Italy
Locations

UOC Ematologia AO Cosenza
Cosenza, Italy

Ematologia AOU S.Anna
Ferrara, Italy

Ematologia AOU Careggi
Firenze, Italy

ASST Lecco Ospedale A.Manzoni
Lecco, Italy

UOC Ematologia ATMO
Livorno, Italy

ASST Grande Ospedale Metropolitano Niguarda
Milano, Italy

SCDU Ematologia
Novara, Italy

Dipartimento Oncologico La Maddalena
Palermo, Italy

UOC DI ONCOEMATOLOGIA AOR Villa Sofia - Cervello
Palermo, Italy

Ematologia Università "Sapienza" Roma
Roma, Italy

IRCCS Istituto Clinico Humanitas
Rozzano, Italy

UOC Ematologia Casa Sollievo della Sofferenza
San Giovanni Rotondo, Italy

SCDU Ematologia e terapie cellulari AO Mauriziano
Torino, Italy

Ematologia Ospedale S.Chiara
Trento, Italy

UOC ematologia ULSS2 Marca Trevigiana
Treviso, Italy

Contacts

Paola Fazi
0670390528
p.fazi@gimema.it

Enrico Crea
0670390514
e.crea@gimema.it

Gian Matteo Rigolin, Principal Investigator
Ematologia - Azienda Ospedaliero Universitaria S.Anna di Ferrara

Fondazione Italiana Linfomi
NCT Number
MeSH Terms
COVID-19
Lymphoma
Leukemia
Lymphoma, Non-Hodgkin
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, B-Cell